{"name":"Ryvu Therapeutics SA","slug":"ryvu-therapeutics-sa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"RVU120","genericName":"RVU120","slug":"rvu120","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"RVU120","genericName":"RVU120","slug":"rvu120","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNbnBHaVFCMDNjZE41YS0xREMycU5jUWtuV2d3RlZicVZPVTNlaWtTdko3V3NVY2U2bXJsaXgxclNJMDAzbnEtVlJscF94aG1RT2pMT2UzVmhfNjA1amhsdWF1cEdZazBCNnZEX3ZQaUNzeWlBdmgxYzRNb2dPLUJhUktyVllQY2UwYjVqVklGOWRSMzhzUERhd0JlQ1lzRlBtQ2paZXNJaURtLWF4Nk1ZdjZPdU4xVmY4U1FSV0hOVmRlam96dXdWS1hUYWVBNmJ2ZWNNVlM3Y28zUE1YMkxvU09hX05HUkpBOGJvRlJTNG9FMUdQT2Q0aVl3bS02V0d1aXlJ?oc=5","date":"2026-04-02","type":"pipeline","source":"Barchart","summary":"Non-Hodgkin Lymphoma Treatment Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart","headline":"Non-Hodgkin Lymphoma Treatment Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry |","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNSWJlQUtVYmJwNUxsZGZtV3E5MkluYUdsY1dpVWhweFBvaDhTaG9FTEpBcmxOSDhLVzhWbUN4U0RSWG10TXhnWXVPLWdTQ1daWUtSME9wQktCaW1EczZFbGdBdVo4aW1udnVPYXB3WXpSM2g4WW5UeFptRWhZeGFMYjY5bUxGcDliYWtJLWRLYjdIQ0JMYXFUS18wTFE3Yjh2bl9jTkhJaEJrYzIyX0NxN2d4QlR2SldHVlkwV29hNjQtQQ?oc=5","date":"2026-04-02","type":"pipeline","source":"AD HOC NEWS","summary":"Ryvu Therapeutics S.A. Stock: Navigating Oncology Innovation and Biotech Investment Opportunities fo - AD HOC NEWS","headline":"Ryvu Therapeutics S.A. Stock: Navigating Oncology Innovation and Biotech Investment Opportunities fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUXpLbUZFSzEwTVFicjZ3MzNOa3FvZ04zN0d0a09VcjRRZ3pTTTVQdGdlVUFYNHE2T1U5V0N5YUVTMGpxWHh2aG11blREWXlfNDQyNGo0UmxfVWVEVlQxdXlSRUVNTVBDMkpDMXNLOUVaLWt1WEdQZmdpZUl1dGtxUE53RTlfU3lSQ3k3b0RmUHhZNVY4bVZUN2NfaXRZOE1WX1FrWDBRaFpFV2Y3RjZaMFdSREM5XzRwUGRSOQ?oc=5","date":"2026-03-19","type":"pipeline","source":"AD HOC NEWS","summary":"Ryvu Therapeutics S.A. Aktie: Fresh Pipeline Momentum Drives Biotech Interest Amid Clinical Advances - AD HOC NEWS","headline":"Ryvu Therapeutics S.A. Aktie: Fresh Pipeline Momentum Drives Biotech Interest Amid Clinical Advances","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-07","type":"pipeline","source":"simplywall.st","summary":"Why Investors Shouldn't Be Surprised By Ryvu Therapeutics S.A.'s (WSE:RVU) 30% Share Price Surge - simplywall.st","headline":"Why Investors Shouldn't Be Surprised By Ryvu Therapeutics S.A.'s (WSE:RVU) 30% Share Price Surge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPOEJzQW5qZTRBalY2QXdJanVieVVNSngta1phZ3UtTEpRZjJMY2hJcjBiXzVGWFh4NU5hMnkySmxiUUJLSlJ6ZEpsWmlweExLY1Bma2pJQV9HTElicHhvOEU5bjM5V3IyU1h1RmNuSHVHMGlfU3JkY3E2WUFIZ3dkTDBEY0xxX04xc1dIZ2lOQWp3OWZZTWdOMU04LUVOU2NqdXFIMjAtQ3lmc1F1Q2tzNTlqTEtXVnd5R0dmTkdvekUxdkhlampENGp1eU1qcmxWRk83eFZLQVluazdvNU1uR1VZZ1dCRjFs?oc=5","date":"2025-09-03","type":"pipeline","source":"PR Newswire","summary":"Myelofibrosis Market is Going to Grow at a CAGR of 9% in the Next Ten Years (2025-2034) | DelveInsight - PR Newswire","headline":"Myelofibrosis Market is Going to Grow at a CAGR of 9% in the Next Ten Years (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNaVY5X0YtQXE3Z3dJdm5lLWxkZ0RIZzF5dm8wR21pV091RnFraTNWVTlCcG1sMTFidEhMcEpucVd6RlRCc0dqQjlNNm5rTklHN0FYTGZ2NDFDQk5Cd1BCbGdWQXRGNThFaWdDTFJLZXB0N21XMDMxbE9fRVFCQjkyVWFZZGFVSmhIclNyRENpckhNalJuaFd3?oc=5","date":"2025-02-25","type":"pipeline","source":"The Pharma Letter","summary":"Poland’s Ryvu Therapeutics announces strategic reorganization - The Pharma Letter","headline":"Poland’s Ryvu Therapeutics announces strategic reorganization","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQaDRGeGFLVjZLZFYtMVNMblZfc3Q5ODNPb3lwQ1hHT2ZUNXpxWjdobm5pbER1SWYxZkcyQ1N6eHc5SFlLRXAtZzR1enA4VlBNZjdnZGdnVG1IOFAwOU5zWWRBR1pSOGdNRzBuaUVYbXNXV2h4bHZ3XzhkS1dxR2RqSVpMUzBQSWE4Ty1RejJwbmpITFJ3ZFJ5bEEwSUREUDcxenZJLXAzRC01Q3AwT3A0OFFTaUg?oc=5","date":"2025-02-25","type":"trial","source":"Fierce Biotech","summary":"Polish biotech Ryvu waves goodbye to 30% of staff in focus on phase 3 blood cancer trials - Fierce Biotech","headline":"Polish biotech Ryvu waves goodbye to 30% of staff in focus on phase 3 blood cancer trials","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}